Equillium/$EQ

1D1W1MYTD1Y5YMAX

About Equillium

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Ticker
$EQ
Sector
Health
Primary listing
NASDAQ
Employees
15
Headquarters
La Jolla, United States
Website
www.equilliumbio.com

Equillium Metrics

BasicAdvanced
$130M
-
-$0.20
1.81
-

Equillium News

AllArticlesVideos

EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon

Reuters1 day ago

EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake

Accesswire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.